An international survey to better understand the current incidence, severity, and management of VOD/SOS
- PMID: 39375526
- DOI: 10.1038/s41409-024-02434-9
An international survey to better understand the current incidence, severity, and management of VOD/SOS
Abstract
This international questionnaire survey aimed to explore the current incidence, diagnostic policies, management, and outcomes of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) among healthcare providers involved in the management of these patients. A questionnaire was e-mailed to practitioners with an interest in allogeneic hematopoietic cell transplantation (allo-HCT). Of the respondents, 144 of 215 (67.0%) felt that early detection or diagnosis of VOD/SOS was difficult. Regarding diagnostic criteria, 142 (66.1%) already declared using the 2023 EBMT refined criteria. Most respondents (163/215, 75.8%) found these recent refined EBMT criteria useful for diagnosis, and 193 (89.8%) found the severity criteria easy to use. The major risk factors identified for VOD/SOS were a second allo-HCT (41.4%), pre-existing liver disease (54.9%), and prior use of antibody-drug conjugates (49.8%). Preferences for starting VOD/SOS treatment varied, with 61 (28.4%) preferring initiating therapy at a mild stage, and 122 (56.7%) preferring the moderate stage. In summary, this survey provided valuable insight into the challenges and opportunities of the identification and management of VOD/SOS. By improving current knowledge and increasing collaboration among healthcare professionals, early detection, management, and clinical outcomes for patients with this potentially serious complication can also be improved.
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: Ahmed Alaskar: Received honoraria/consultancy fees: Novartis, Abbvie, Janssen, Takeda, Kyowa Kirin, Gilead, Roche, Sanofi. Participated in company sponsored speakers bureau: Janssen, Kyowa Kirin, Sanofi. Michelle Kenyon: Received honoraria/consultancy fees: Jazz Pharmaceuticals, Sanofi, Roche, Mallinkrodt, Vertex. Speakers bureau: Jazz Pharmaceuticals, Sanofi, Pfizer. Ethics approval: The IACH steering committee ( www.iach.org ) approved the conduct of this survey according to standard professional practices.
References
-
- Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018;53:138–45. - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources